News

Viopas Venture Consulting (VVC) congratulates its Managing Partner Thomas Meier, PhD, for his appointment as Board member of Onconetix Inc. (NASDAQ: ONCO)

View on LinkedIn

Viopas Venture Consulting (VVC) congratulates its Managing Partner Ulf Grawunder, PhD, for his recent appointment as independent non-executive director on the Board of WuXi XDC

View on LinkedIn

Viopas Venture Consulting (VVC) congratulates Proteomedix AG and Blue Water Biotech Inc. for their share exchange transaction to launch Onconetix Inc.

View on LinkedIn

Viopas Venture Consulting strengthens its biopharma business development and licensing expertise by appointing Knut Sturmhoefel, PhD as Partner

View on LinkedIn

Viopas Venture Consulting congratulates Santhera Pharmaceuticals for obtaining the U.S. FDA marketing authorization for vamorolone for the treatment of patients with DMD

View on LinkedIn

Viopas Venture Consulting congratulates Santhera Pharmaceuticals for the positive recommendation by the CHMP to approve vamorolone for the treatment of patients with DMD

View on LinkedIn

Viopas Venture Consulting congratulates Bird Rock Bio for the business combination with Skye Bioscience

View on LinkedIn

Viopas Venture Consulting opens office in the Innovation and Start-up Center Biotechnology (IZB) near Munich

View on LinkedIn

Viopas Venture Consulting joins Swiss Healthcare Startups (SHS) as industry member. SHS represents over 600 healthcare startup companies in Switzerland

View on LinkedIn

Viopas Venture Consulting managing partner Thomas Meier, PhD attends and presents at the upcoming Swiss-Chinese Life Science Forum 2023 organized by the Swiss-Chinese Chamber of Commerce, Basel Area and Vischer

View on LinkedIn

Viopas Venture Consulting partner Tom Loeser appointed as CFO of T-CURX, a biopharmaceutical company focused on identifying, developing and commercializing next generation CAR-T cell therapies in cancer

View on LinkedIn

Viopas Venture Consulting strengthens expertise in CMC, Technical Operations, Supply Chain and QA by appointing Rudolf Hausmann, PhD as Partner

View on LinkedIn

Viopas Venture Consulting strengthens medical expertise in the field of ophthalmology by appointing Marcia de Souza Lima, MD as Partner

View on LinkedIn

Viopas Venture Consulting announces the appointment of Thomas Loeser as new Managing Partner and plans business expansion to life science hub in Munich, Germany

View on LinkedIn

Viopas Venture Consulting forms strategic partnership with evisory, adds expertise in Digital HealthCare and Technology

Uster/Zürich, Switzerland, May 04, 2022 – Viopas Venture Consulting, dedicated advisor to biotech, pharma and digital health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, and evisory, a Swiss-based advisory firm to the digital healthcare and technology industry, announce their strategic partnership.

Download full news release here.

Viopas Venture Consulting forms strategic partnership with Dao Tun, adds expertise in cross-border cooperation with China

Uster/Zürich, Switzerland, March 22, 2022 – Viopas Venture Consulting (VVC), dedicated advisor to biotech, pharma and digital health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, and Dao Tun GmbH, a Swiss advisory consulting company specialized in cross-border cooperation between Europe and China, announce their strategic partnership, which leverages VVC's current business model by offering cross-border strategic advice for clients interested in business relations in China.

Download full news release here.

Viopas Venture Consulting forms strategic partnership with Michele Pedrocchi, PhD

Uster/Zürich, Switzerland, March 9, 2022 – Viopas Venture Consulting, dedicated advisor to biotech, pharma and digital health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, and Michele Pedrocchi, PhD, announce their strategic partnership.

Download full news release here.

Board Advisors (Deutschland) and Viopas Venture Consulting acted as financial advisors and led a EUR 1.3 million equity financing in DyCare's innovative tele-rehabilitation and digital care solutions

Freiburg, Germany and Uster/Zürich, Switzerland, February 22, 2022 – Board Advisors (Deutschland) AG and Viopas Venture Consulting GmbH acted as financial advisors and contributed EUR 785'000 in an equity financing of EUR 1.3 million for Bio-Sensing Solutions' DyCare. The financing was conducted under a mandate to Board Advisors and the investment contribution was executed via newly created CareInvest AG, a Swiss-based holding structure of Viopas Venture Consulting. The proceeds of the financing will support the commercial roll-out of the company's innovative digital physiotherapy and tele-rehabilitation product ReHubTM. Simon Nebel, PhD, Partner at Board Advisors and Managing Partner at Viopas Venture Consulting will join the Board of Directors of Bio-Sensing Solutions, the legal owner of DyCare.

Download full news release here.

Thomas Meier, PhD, Managing Partner at Viopas Venture Consulting, joins the Board of Directors of Visgenx, Inc.

Uster/Zürich, Switzerland, January 17, 2022 – Viopas Venture Consulting, dedicated advisor to Biotech, Pharma and Digital Health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, announces today that Managing Partner Thomas Meier, PhD, joins the Board of Directors of Visgenx Inc., San Diego, CA (USA).

Download full news release here.

Ulf Grawunder, PhD, Managing Partner at Viopas Venture Consulting presents at upcoming conferences

Uster/Zürich, Switzerland, January 13, 2022 – Viopas Venture Consulting, dedicated advisor to Biotech, Pharma and Digital Health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, announces today that managing partner Ulf Grawunder, PhD, will present at upcoming conferences.

Download full news release here.

Viopas Venture Consulting welcomes Ulf Grawunder, PhD, and Daniel Pajer as new Managing Partners

Uster/Zürich, Switzerland, December 01, 2021 – Viopas Venture Consulting, dedicated advisor to Biotech, Pharma and Digital Health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, announces today the engagement of Ulf Grawunder, PhD, and Daniel Pajer as new Managing Partners.

Download full news release here.

Viopas Venture Consulting participates at remote Spark Night event organized by ETH Zürich

Viopas Venture Consulting (VVC) participated as advisor to the Spark Night Pharma and MedTech events organized as remote presentations by the ETH Zürich. Presenting start-up companies in the Pharma/Biotech track were EraCal, InCephalo Therapeutics and Phire Therapeutics and presenting in the MedTech track were aiEndoscopic, Resmonics and Quantactions.

“We are delighted to have participated in the Spark Night event organized by the ETH Zürich and congratulate the start-up companies to their progress,” said Simon Nebel PhD, MBA, Managing Partner at VVC.

Viopas Venture Consulting participates at Startup Investment Day of ZHAW

Viopas Venture Consulting (VVC) participates as advisor to the Startup Investment Presentations by the Zurich University of Applied Sciences (www.zhaw.ch). Presenting companies were Resmonics.ai, Nala.care and Leitwert.

“We actively seek to engage very early with promising companies in the healthcare sector to scout for attractive investment opportunities for our investor clients and offer our support for young companies in strategic positioning and fund raising,” said Simon Nebel PhD, MBA, Managing Partner at VVC. “We would like to thank the organizers of ZHAW for inviting us to this event ad thank the participating companies for their presentations”

Viopas Venture Consulting advises Dachverband der Sozialversicherungsträger (Austria)

Viopas Venture Consulting (VVC) advises the Dachverband der Sozialversicherungsträger in Österreich, SV (the Umbrella Organization for Social Services and Health Insurances in Austria) in the evaluation of innovative digital health technologies that might strengthen Austrian public health sector.

“We are pleased having been invited by an expert team of the SV to contribute as external experts in the company pitch day where a series of emerging digital health companies from across Europe presented their technologies and business models,” explained Simon Nebel PhD, MBA, Managing Partner at VVC.

Viopas Venture Consulting team appointed as Partners of Board Advisors Deutschland AG

Board Advisors Deutschland AG publicly announced the expansion of their advisory services into the Digital Health industry sector and the appointment of Dr. Simon Nebel and Dr. Thomas Meier as Partners.

“We are very pleased that Thomas and Simon will strengthen our team. Relying on their expertise Board Advisors will be able to widen our products and services from the focus area of IT, software, SaaS and IT services into the rapidly growing sector of digital health”, commented Christoph Löslein (Founding Partner at Board Advisors).

“Being part of the Board Advisors team clearly strengthens our reach into the IT world where SaaS business models are well established. The overlap of IT and Digital Health clearly leverages technologies and business concepts, creating attractive investment opportunities”, commented Thomas Meier, PhD, Managing Partner at VVC.

For more information, please see www.boardadvisors.de